Skip to search formSkip to main contentSkip to account menu

CYP2C19*2 Allele

Known as: CYP2C19, m1A, CYP2C19, c.681G>A, CYP2C19, m1 
Human CYP2C19*2 allele is located within 10q24.1-q24.3 and is approximately 90 kb in length. This allele, a variant form of the CYP2C19 wild-type… 
National Institutes of Health

Related topics

Related topics

13 relations
10q24.1-q24.3Frameshift Mutation functionGuanosine to Adenosine Transition AbnormalityInactive - Biochemical Activity Level

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population
The extent to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of clopidogrel remains uncertain due to… 
2014
2014
ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
2012
2012
Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
BACKGROUND Antiplatelet properties of omega-3 polyunsaturated fatty acids (PUFA) have been demonstrated in patients with coronary… 
Highly Cited
2011
Highly Cited
2011
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Highly Cited
2011
Highly Cited
2011
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
AIMS In clopidogrel-treated patients undergoing coronary stenting, high on-treatment platelet reactivity was linked to a higher… 
2011
2011
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood
Lansoprazole, a cytochrome P450 2C19 (CYP2C19) substrate, has been widely used in children to manage acid-related diseases… 
2010
2010
SCREENING FOR CYP2C19*2, *3 AND *4 GENE VARIANTS IN A ROMANIAN POPULATION STUDY GROUP
CYP2C19, a member of the cytochrome P450 enzymes family, metabolizes a range of clinically significant drugs. Its homologous gene… 
2000
2000
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
AIMS Terodiline has concentration dependent QT prolonging effects and thus the potential for cardiotoxicity. Pharmacogenetic… 
Highly Cited
1999
Highly Cited
1999
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
AIMS CYP2D6 and CYP2C19 are polymorphically expressed enzymes that show marked interindividual and interethnic variation. The aim… 
Highly Cited
1998
Highly Cited
1998
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
The 4'-hydroxylation of the S-enantiomer of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in humans. This… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)